-- 加拿大皇家銀行資本市場將加拿大國家鐵路公司(CNR.TO,CNI)的目標股價從160美元上調至178美元,並將加拿大太平洋堪薩斯市有限公司(CP.TO,CP)的目標股價從128美元下調至127美元。 分析師沃爾特·斯普拉克林(Walter Spracklin)在兩家加拿大鐵路公司公佈季度業績後,維持了對它們的“跑贏大盤”評級。 斯普拉克林在給客戶的報告中表示:「儘管加拿大國家鐵路公司的業績與市場預期相符(值得注意的是,在季度報告發布前,市場預期有所上調),但市場預期該公司在第一季度會像美國同行那樣實現更高的運營槓桿,而這一預期並未實現,導致股價在早期出現拋售。” 這位分析師表示:“關鍵在於,我們認為這只是對業績報告的過度反應,因為管理層在電話會議上很好地指出了我們認為是第一季獨立成本的部分。” “我們預計營運槓桿將在今年內逐步提升,並看好業績指引和市場預期。” 「我們預期CP股價將面臨一定壓力,原因是其第一季業績低於預期,且全年業績指引面臨風險,」斯普拉克林表示。 「值得注意的是,一家主要客戶的煤炭生產出現問題,這被認為是導致銷售量下降100個基點的阻力,」這位分析師說。 “儘管管理層預計第二季度業績將環比大幅改善,但我們已將MSD銷量和LDD每股收益的預期下調至管理層預期範圍的極低水平,並指出存在下行風險。”
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%